Last reviewed · How we verify

NVX-CoV2373 + NVX-CoV2515 — Competitive Intelligence Brief

NVX-CoV2373 + NVX-CoV2515 (NVX-CoV2373 + NVX-CoV2515) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine SARS-CoV-2 spike protein (original strain and Omicron variant) Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

NVX-CoV2373 + NVX-CoV2515 (NVX-CoV2373 + NVX-CoV2515) — Novavax. A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NVX-CoV2373 + NVX-CoV2515 TARGET NVX-CoV2373 + NVX-CoV2515 Novavax phase 3 Recombinant protein vaccine SARS-CoV-2 spike protein (original strain and Omicron variant)
Licensed seasonal influenza vaccine Licensed seasonal influenza vaccine Novavax marketed Recombinant protein vaccine with adjuvant Influenza hemagglutinin (HA) protein
Recombinant influenza hemagglutinin Recombinant influenza hemagglutinin Vaxine Pty Ltd marketed Recombinant protein vaccine Influenza hemagglutinin
Licensed 4CMenB vaccine Licensed 4CMenB vaccine University of Adelaide marketed Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens
FluBlok FluBlok The University of Hong Kong marketed Recombinant protein vaccine Influenza hemagglutinin (HA)
Meningococcal B (Bexsero) Meningococcal B (Bexsero) University of Sao Paulo General Hospital marketed Recombinant protein vaccine Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Novavax recombinant protein vaccine Novavax recombinant protein vaccine Henry M. Jackson Foundation for the Advancement of Military Medicine marketed Recombinant protein vaccine Viral surface antigens (e.g., SARS-CoV-2 spike protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

  1. GlaxoSmithKline · 6 drugs in this class
  2. Novavax · 5 drugs in this class
  3. Vaxine Pty Ltd · 2 drugs in this class
  4. D'Or Institute for Research and Education · 2 drugs in this class
  5. Protein Sciences Corporation · 2 drugs in this class
  6. Henogen · 1 drug in this class
  7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
  8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
  9. National Vaccine and Serum Institute, China · 1 drug in this class
  10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NVX-CoV2373 + NVX-CoV2515 — Competitive Intelligence Brief. https://druglandscape.com/ci/nvx-cov2373-nvx-cov2515. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: